ClinicalTrials.gg
Active, not recruitingNCT07177157PIVDUpdated Oct 5, 2026

The Prospective Improved Vitamin D Study for Inflammatory Bowel Disease Patients

A Phase 1 interventional study of Vitamin D3 (Cholecalciferol) in Ulcerative Colitis (UC), IBD (Inflammatory Bowel Disease) and Crohn Disease (CD), sponsored by Terry Ponich. Active, not recruiting at 1 site in Canada. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Terry Ponich · Phase 1, Interventional, and Treatment

How we know

Updated Oct 5, 2026Now Active, not recruitingStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 265 studies in Colitis, Ulcerative with a site in Canada — 47 open to participants now, 84 under way, 24 of them phase 3. Colitis, Ulcerative · Canada.

Planned enrollment
118th of 227
150 · median 162
Started
2025
with 17 others
Phase 1
12 of 265
3 open now
Primary completion
2027-07
later than 44 of 83 live
Registered
246th of 265
by date

Among the 265 studies in Colitis, Ulcerative with a site in Canada, this one is the 118th largest by planned enrollment of the 227 interventional ones that give a count, is one of 18 that started in 2025, is one of 12 in phase 1, reaches primary completion later than 44 of the 83 other live ones, and was the 246th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

47 of the 265 studies in Colitis, Ulcerative with a site in Canada are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 265 studies in Colitis, Ulcerative with a site in Canada, or all of them as a file.
02

Study summary

The aim of this clinical trial is to gain a better understanding of the effect of Vitamin D supplementation on disease activity and overall health. The main questions it aims to answer are:

  1. What proportion of IBD patients adhere to Vitamin D supplement recommendations over a 12-month period?
  2. Is the ASK-12 Questionnaire valid in measuring adherence among IBD patients?
  3. Does the severity of a patient's Crohn's disease effect overall adherence, over a 12-month period?
  4. Does the severity of a patient's Ulcerative Colitis disease effect overall adherence, over a 12-month period?
  5. Does Vitamin D supplementation affect the health-related Quality of Life for IBD patients?
  6. Is 2,000 IU/Day an effective dose to sustain appropriate blood Vitamin D levels among previously Vitamin deficient IBD patients?

Participants will:

  • Take 2000 IU of Vitamin D every day for the next 12 months
  • Complete 2 surveys, bloodwork and a fecal calprotectin test at the initial, visit, 6 month follow up and 12 month follow up
Read the detailed description

Upon investigating the literature, despite there being a lot of medication compliance research, there was not much research catered to IBD patient medication management specifically.

Vitamin D supplementation based on immune-modulatory effects alongside its beneficial effects on bone health can lead to reduced rates of osteopenia and osteoporosis in the IBD population. In the treatment of IBD, the major patient care objectives to relieve symptoms and reduce inflammation doesn't leave much time or consideration for other aspects of patient care such as Vitamin D supplementation.

This study will investigate the gastroenterology department at LHSC to assess the current state of adherence and monitoring of Vitamin D and other medications for both Crohn's disease and ulcerative colitis patients. This will be done through a prospective cohort study of patients whose records have stated that they are not currently on Vitamin D. Through assessing overall adherence, foundational understanding of the IBD population will be obtained and the use the ASK-12 questionnaire will be validated. Once done, this would allow for a broader understanding of the patient specific factors affecting individual adherence and lay the foundation for research into ways at increasing adherence among non-adherent individuals.

The overall objective of this study is to estimate the proportion of patients that adhere to Vitamin D supplements. It is the hope that through investigations Vitamin D monitoring and adherence can be standardized at LHSC and long term osteoporosis and osteopenia complications commonly experienced by the IBD patient population can be prevented.

The central hypothesis is that Vitamin D adherence among IBD patients is low and that it is closely related to the patient's IBD disease severity. It is anticipated for this Vitamin D trend to be reversed, as patients may want to stabilize the disease condition and limit acute exacerbations prior to restarting maintenance therapy in the form of Vitamin D treatment.

A clinician as part of the gastroenterology team at Victoria Hospital or St. Joseph's Hospital (Dr. Ponich and other members of VH GI team) who is the primary healthcare contact for the recruited patient will make initial contact with potential participants. Dr. Ponich or another member of the VH GI team will approach the patient in clinic after their visit and ask a member of the research team to discuss the purpose and procedure of the study. The research team member will have the patients fill out a short-written consent form that meets the standards at LHSCRI as submitted in the WREM application. The research team member will obtain written consent from the patient.

Recruited patient's will be provided Vitamin D supplementation and be asked to take 2,000 IU/day. No additional reinforcement will be provided to these patients. At both 6- and 12-month intervals, remaining supplements will be collected, and overall adherence will be assessed. Participants will be asked to complete the EQ-5D-5L to assess their health-related quality of life and the ASK-12 Questionnaire, which will be compared to the pill counts, to determine the validity of ASK-12 among IBD patients. The Patients' IBD will be assessed by performing either a Partial Mayo or CDAI Score as well as completing a fecal calprotectin test. Additionally, participant serum Vitamin D levels will be collected to determine whether adherence to medication resulted in an identifiable increase.

03

Conditions studied

  • Ulcerative Colitis (UC)
  • IBD (Inflammatory Bowel Disease)
  • Crohn Disease (CD)

Keywords

  • vitamin D
  • Inflammatory Bowel Disease
  • IBD
  • Ulcerative Colitis
  • Bone Health
  • Immune Modulation
  • Crohn Disease (CD)
04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults Aged 18-85
  2. Diagnosis of IBD (Ulcerative Colitis or Crohn's Disease) within the patient's records based on standard clinical, endoscopic, and radiologic criteria.
  3. Patients within outpatient gastroenterology clinics at Victoria Hospital and St. Joseph's Hospital with follow-up appointments within the next 2 years (ongoing IBD care).
  4. Participants must have the ability to read, comprehend, and voluntarily provide without assistance.

Exclusion criteria

Exclusion Criteria:

  1. Those who do not meet the inclusion criteria.
  2. Those with any concurrent diagnosis of a disease that may affect calcium or vitamin D metabolism (i.e., thyroid disease, parathyroid disease, primary bone disease, granulomatous disease, sarcoidosis, lymphoma).
  3. Those with renal dysfunction (serum creatinine >0.150 mmol/L), those receiving dialysis, or those with hypercalcemia (>2.65 mmol/L).
  4. Those with advanced liver disease (Note: individuals with mild liver disease may be included at the physician's discretion).
  5. Those using continuous oral for the management of any disease other than IBD.
  6. Those with a history of vitamin D supplementation within 6 months prior to the trial.
  7. Those who are unable to attend follow-up appointments with the gastroenterology team.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Vitamin D

    Participants who have IBD (UC or CD) will receive Vitamin D3 and will take a 2000 IU pill daily for 12 months.

    Dietary Supplement: Vitamin D3 (Cholecalciferol)

Interventions

06

What researchers measure

Primary outcomes

  1. Medication Adherence

    Assessing the proportion of IBD patients, at both 6 and 12 months, who are adherent to Vitamin D supplementation using pill-counting of supplements provided to them.

    Time frame: Enrollment to 12 month follow up

Secondary outcomes

  1. Validity of ASK-12 Survey

    Determining the validity of the ASK-12 survey, a 12-item Short Health Survey adherence tool will be used to assess adherence rates, among the IBD patients. The ASK-12 Questionnaire detects patient specific barriers to medication adherence, with scores ranging from 12-60 (higher scores indicating a greater non-adherence). The ASK-12 also contains 3 separate subscales: (1) Adherence Behaviors, (2) Health Beliefs, (3) Inconvenience/Forgetfulness.

    Time frame: Enrollment until 12 month follow up

  2. Quality of Life Assessment

    Assessing the change in quality-of-life among IBD patient's using the EQ-5D-5L survey to assess the general health among the patient population. The EQ-5D-5L Health Survey is a 5- item survey that assesses both physical and mental health. There are 5 subcategories that consist of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. There is also a scale where the patient assesses their current overall health ranging from 0 (the worst health they can imagine) to 100 (the best health they can imagine). This tool will be used to compare any changes in health-related quality of life among IBD patients based on their individual rates to supplementations.

    Time frame: Enrollment until 12 month follow up

  3. Crohn's Disease - Disease Severity

    Assessing the patient's Crohn's Disease severity using the Crohn's disease activity index (CDAI) respectively. The CDAI is a validated tool in assessing disease severity among Crohn's disease patients, with a score \>150 indicative of active disease. Any other scores would indicate that the disease is in remission. It will also be looked at by testing fecal calprotectin levels which will allow for comparison of the level of inflammation.

    Time frame: Enrollment until 12 -month follow up

  4. Ulcerative Colitis - Disease Severity

    Assessing the patient's Ulcerative Colitis disease severity using the Mayo Disease Activity Index (DAI) respectively. The DAI is a validated tool used in assessing disease severity among Ulcerative Colitis patients, with a score \>2 indicative of active disease. Any other scores would indicate that the disease is in remission. It will also be looked at by testing fecal calprotectin levels which will allow for comparison of the level of inflammation.

    Time frame: Enrollment until 12-month follow up

  5. Impact on Serum Vitamin D Levels

    Assessing the effect that providing 2,000 IU/Day of Vitamin D supplements would have on the Serum Vitamin D of IBD patients. Serum Vitamin D levels will be collected and compared to the patient's individual adherence levels using the pill-counting method.

    Time frame: Enrollment until 12 month follow up

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jul 2027, 20 months after the start.

Of 84 phase 1 interventional studies under Colitis, Ulcerative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 20 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: start Oct 2025 → Nov 2025, primary completion Mar 2027 → Jul 2027 and completion Mar 2027 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2025
First posted
Sep 16, 2025
StartActual
Nov 5, 2025was Oct 2025
Primary completionEst.
Jul 2027was Mar 2027
CompletionEst.
Jul 2027was Mar 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 5, 2026
Start date
Oct 2025→Nov 5, 2025 (actual)
Oct 5, 2026
Primary completion
Mar 2027→Jul 2027
Oct 5, 2026
Study completion
Mar 2027→Jul 2027
Oct 5, 2026
Eligibility
5 exclusion criteria edited, 1 added
What changed in the criteria
Exclusion criteria
  • EditedThose with any concurrent diagnosis of a disease that may affect calcium or Vitaminvitamin D metabolism (i.e., rheumatoid arthritis or other inflammatory joint disease, thyroid disease, parathyroid disease, primary bone disease, granulomatous disease, sarcoidosis, lymphoma).
  • EditedThose with either renal dysfunction (serum creatinine >0.150 mmol/L) or, those receiving dialysis were excluded, patientsor those with chronic liver disease, and hypercalcemia (>2.65mmol65 mmol/L).
  • AddedThose with advanced liver disease (Note: individuals with mild liver disease may be included at the physician's discretion).
  • EditedThose using continuous oral corticosteroids for the management of any disease other than IBD.
  • EditedThose with a history of Vitaminvitamin D or calcium supplementation within 6 months prior to the trial.
  • ChangedBefore Those who were seen once by the gastroenterology team but never followed up (no ongoing IBD care).Now Those who are unable to attend follow-up appointments with the gastroenterology team.
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Not yet recruiting→Active, not recruiting
    Start date Oct 2025→Nov 5, 2025 (now actual)
    Primary completion Mar 2027→Jul 2027
    Study completion Mar 2027→Jul 2027
    Eligibility 5 exclusion criteria edited, 1 added
    What changed in the criteria
    Exclusion criteria
    • EditedThose with any concurrent diagnosis of a disease that may affect calcium or Vitaminvitamin D metabolism (i.e., rheumatoid arthritis or other inflammatory joint disease, thyroid disease, parathyroid disease, primary bone disease, granulomatous disease, sarcoidosis, lymphoma).
    • EditedThose with either renal dysfunction (serum creatinine >0.150 mmol/L) or, those receiving dialysis were excluded, patientsor those with chronic liver disease, and hypercalcemia (>2.65mmol65 mmol/L).
    • AddedThose with advanced liver disease (Note: individuals with mild liver disease may be included at the physician's discretion).
    • EditedThose using continuous oral corticosteroids for the management of any disease other than IBD.
    • EditedThose with a history of Vitaminvitamin D or calcium supplementation within 6 months prior to the trial.
    • ChangedBefore Those who were seen once by the gastroenterology team but never followed up (no ongoing IBD care).Now Those who are unable to attend follow-up appointments with the gastroenterology team.
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07177157
Lead sponsor
Terry Ponich
Responsible party
Terry Ponich (Gastroenterology Team Clinician - Victoria Hospital (LHSC), London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's) — Sponsor-investigator
First posted
Sep 16, 2025
Start date
Nov 5, 2025
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Terry P Ponich, MD, FRCPC
principal investigator · Victoria Hospital - London Health Sciences Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cholecalciferol

Start the discussion